Clinical Trials

1,978 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT05768139 2026-06-04

PIKALO-1

BreastGynecologicHead & Neck

880 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05870579 2026-06-04

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Active not recruiting

48 enrolled

Breast Neoplasms

NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07174336 2026-06-04

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05827081 2026-06-03

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT07492641 2026-06-03

KANDELA-302

1,056 enrolled

HR+/HER2- Breast Cancer

NCT06075758 2026-06-01

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Completed

175 enrolled

Breast Neoplasms

NCT06830720 2026-06-01

CAROLEEN

Recruiting

3,250 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07618390 2026-06-01

A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

160 enrolled

Breast Neoplasms

NCT02645149 2026-05-29

Match Mel

Phase 2 Completed

216 enrolled

Dermatologic

Melanoma

NCT05843253 2026-05-29

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

120 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT07195227 2026-05-29

CADILLAC

150 enrolled

Breast Neoplasms

NCT04862663 2026-05-27

CAPItello-292

895 enrolled

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT06953882 2026-05-26

SELECT

140 enrolled

HER2 Negative Breast Cancer

NCT07054190 2026-05-26

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

60 enrolled

Breast Neoplasms

NCT07237256 2026-05-26

NoLEEta

3,902 enrolled

Breast Neoplasms

NCT03008408 2026-05-22

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

90 enrolled

Gynecologic

Endometrial Neoplasms

NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

48 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06930859 2026-05-22

ELEGANCE

Recruiting

2,766 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT06760637 2026-05-19

FourLight-3

1,035 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

1,180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

80 enrolled

Breast Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT07085767 2026-05-15

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT05296746 2026-05-14

RIBOLARIS

1,100 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT04055493 2026-05-11

ADAPTcycle

1,684 enrolled

Breast Neoplasms

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Active not recruiting

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

18 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06188520 2026-05-11

CYCAD-1

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT06905301 2026-05-05

IMPULSE

Recruiting

240 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03616587 2026-04-30

SERENA-1

396 enrolled

Breast Neoplasms

NCT07400523 2026-04-28

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

446 enrolled

Breast Neoplasms

NCT06726148 2026-04-27

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

280 enrolled

Breast Neoplasms

NCT04116541 2026-04-24

MegaMOST

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Terminated

52 enrolled 31 charts

Genitourinary

Prostatic Neoplasms

NCT05683418 2026-04-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Phase 1 Recruiting

241 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04964934 2026-04-21

SERENA-6

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT02934568 2026-04-16

Ribociclib (LEE011) Rollover Study for Continued Access

22 enrolled

Other solid neoplasm

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

NCT05664893 2026-04-15

CALHYS

Phase 1/2 Withdrawn

HER2 Negative Breast Cancer Not Immediately Operated

NCT04920708 2026-04-14

FAIM

57 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05358249 2026-04-14

KontRASt-03

Phase 1/2 Active not recruiting

74 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Available

BreastGastrointestinalThoracic

Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

86 enrolled

Breast Neoplasms

NCT05467891 2026-04-08

RaPhLRR

200 enrolled

Phase 4 Active not recruiting

Locoregional Recurrence

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

46 enrolled

Other solid neoplasm

Solid Tumors

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled